Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting
Abstract
Share and Cite
Nazha, S.; Tanguay, S.; Kapoor, A.; Jewett, M.; Kollmannsberger, C.; Wood, L.; Bjarnason, G.; Heng, D.; Soulières, D.; Reaume, N.; et al. Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. Curr. Oncol. 2018, 25, 576-584. https://doi.org/10.3747/co.25.4103
Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason G, Heng D, Soulières D, Reaume N, et al. Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. Current Oncology. 2018; 25(6):576-584. https://doi.org/10.3747/co.25.4103
Chicago/Turabian StyleNazha, S., S. Tanguay, A. Kapoor, M. Jewett, C. Kollmannsberger, L. Wood, G. Bjarnason, D. Heng, D. Soulières, N. Reaume, and et al. 2018. "Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting" Current Oncology 25, no. 6: 576-584. https://doi.org/10.3747/co.25.4103
APA StyleNazha, S., Tanguay, S., Kapoor, A., Jewett, M., Kollmannsberger, C., Wood, L., Bjarnason, G., Heng, D., Soulières, D., Reaume, N., Basappa, N., Lévesque, E., & Dragomir, A. (2018). Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. Current Oncology, 25(6), 576-584. https://doi.org/10.3747/co.25.4103